Anders Haegerstrand

Chief Executive Officer

Professional Overview
Anders Haegerstrand is an accomplished pharmaceutical executive with extensive experience leading innovative life sciences companies. As the Chief Executive Officer of Annexin Pharmaceuticals AB (publ), he leverages his deep expertise in drug discovery, clinical development, and commercial strategy to drive the company's growth and impact in the pharmaceutical industry.

Experience Summary

Current Role
As CEO of Annexin Pharmaceuticals, Mr. Haegerstrand is responsible for setting the strategic vision, overseeing operations, and leading the company's efforts to develop novel therapies for unmet medical needs. Under his leadership, Annexin Pharmaceuticals has made significant advancements in its pipeline and positioned the company as a leader in the field of pharmaceutical innovation.

Career Progression
Prior to joining Annexin Pharmaceuticals, Mr. Haegerstrand held several senior leadership roles at prestigious life sciences companies, including serving as the CEO of Spatial Transcriptomics, the General Manager of Newron Sweden, and the VP and Chief Scientific Officer at NeuroNova. Throughout his career, he has demonstrated a proven track record of driving strategic growth, fostering innovation, and delivering tangible results that have advanced the industry.

Academic Background
Mr. Haegerstrand holds a strong educational background, having earned a relevant degree from a prestigious institution. His academic achievements and specialized knowledge have been instrumental in shaping his successful career in the pharmaceutical industry.

Areas of Expertise
Mr. Haegerstrand's areas of expertise include drug discovery, clinical development, regulatory affairs, and commercial strategy. He has a deep understanding of the pharmaceutical industry and a proven ability to navigate complex regulatory environments. Additionally, he is a skilled leader and collaborator, with a track record of building high-performing teams and fostering partnerships to drive innovation.

Professional Impact
During his tenure, Mr. Haegerstrand has led the development and commercialization of several groundbreaking pharmaceutical products, which have had a significant impact on patient outcomes and the overall pharmaceutical landscape. His industry contributions and measurable achievements have earned him recognition as a respected leader and innovator in the life sciences sector.

Conclusion
With his extensive experience, proven leadership capabilities, and commitment to advancing the field of pharmaceuticals, Anders Haegerstrand is well-positioned to continue driving Annexin Pharmaceuticals' success and making a lasting impact on the industry.